Transformation of a new scientific idea into a new oncology-based drug requires a tremendous amount of time, effort and investment. The […]
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Patenting the Microbiome – Part 2: Microbiome IP Panel, 2017 BIO Convention Read Post »
Get Customized Access to DrugPatentWatch’s Rich Database DrugPatentWatch provides deep actionable business intelligence on small-molecule drugs and the 1.3 million
Integrate DrugPatentWatch Into Your Application or Data Store Read Post »
Globalization has disrupted many industries, initially shifting unskilled labor employment from high wage-cost industrialized nations to lower wage-cost emerging economies.
Where are Drugs Invented, and Why Does it Matter? Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
This is a guest post from Michael D. Hooven, President & CEO, Enable Injections Inc. The oxpecker perches on the backs
Solving the problem of biologic delivery: Large volume wearable injectors Read Post »
Hermann A. M. Mucke*, H. M. Pharma Consultancy, Wien, Austria A Multimodal Approach to the Re-development of Drugs Drug repositioning—the investigation, development and use of active pharmaceutical ingredients for a…
The post Drug Repositioning in the …
Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory Read Post »
This is a guest post from Craig Stropkay. Craig is Director and Life Science Consultant at KOLgroups, LLC Reach for the
These are relative terms. If I license a product from you, I am in-licensing it and you are out-licensing it.
What is in licensing and out licensing in pharmaceutical sector? Read Post »
This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the
3 Tips for Finding the Right Talent for Your Biotech Startup Read Post »
Get new actionable insights and updates from BiotechBlog
